Gelderblom H - Search Results

1

Clinical pharmacokinetics of tyrosine kinase inhibitors.

van Erp NP, Gelderblom H, Guchelaar HJ. van Erp NP, et al. Among authors: gelderblom h. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. Cancer Treat Rev. 2009. PMID: 19733976 Review.

2

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. Sparreboom A, et al. Among authors: gelderblom h. Cancer Res. 1999 Apr 1;59(7):1454-7. Cancer Res. 1999. PMID: 10197613

3

Oral topoisomerase 1 inhibitors in adult patients: present and future.

Gelderblom HA, DE Jonge MJ, Sparreboom A, Verweij J. Gelderblom HA, et al. Invest New Drugs. 1999;17(4):401-15. doi: 10.1023/a:1006394610219. Invest New Drugs. 1999. PMID: 10759406 Review.

4

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

Gelderblom H, Loos WJ, Verweij J, van der Burg ME, de Jonge MJ, Brouwer E, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Eur J Cancer. 2002 Jan;38(1):205-13. doi: 10.1016/s0959-8049(01)00348-3. Eur J Cancer. 2002. PMID: 11750851

5

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C. Gelderblom H, et al. Clin Cancer Res. 2003 Sep 15;9(11):4101-7. Clin Cancer Res. 2003. PMID: 14519632 Clinical Trial.

6

[Several patients with a metastasised gastrointestinal stroma-cell tumor for whom the tide turned by the introduction of imatinib].

Gelderblom H, Verweij J. Gelderblom H, et al. Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2041-3. Ned Tijdschr Geneeskd. 2003. PMID: 14606347 Dutch.

7

[Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].

Gelderblom H, Hogendoorn PC, van der Graaf WT, Verweij J. Gelderblom H, et al. Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2051-5. Ned Tijdschr Geneeskd. 2003. PMID: 14606351 Review. Dutch.

8

Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.

de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, Cats A, Morreau H, Gelderblom H, Vasen HF. de Vos tot Nederveen Cappel WH, et al. Among authors: gelderblom h. Int J Cancer. 2004 Apr 10;109(3):468-71. doi: 10.1002/ijc.11712. Int J Cancer. 2004. PMID: 14961589

9

Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.

Kweekel DM, Gelderblom H, Guchelaar HJ. Kweekel DM, et al. Among authors: gelderblom h. Cancer Treat Rev. 2005 Apr;31(2):90-105. doi: 10.1016/j.ctrv.2004.12.006. Cancer Treat Rev. 2005. PMID: 15847979 Review.

10

Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.

Cremers SC, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van der Rijt CC, van Zuylen L. Cremers SC, et al. Among authors: gelderblom h. J Bone Miner Res. 2005 Sep;20(9):1543-7. doi: 10.1359/JBMR.050522. Epub 2005 May 31. J Bone Miner Res. 2005. PMID: 16059626

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results